Summit Therapeutics (SMMT) investor relations material

Key accomplishments and clinical progress

• Fourteen phase 3 clinical trials for ivonescimab have been launched globally, with over 3,000 patients treated in trials and more than 40,000 in the commercial market in China.

• Harmony 6 demonstrated a strong PFS signal, confirming the benefit of ivonescimab in combination with chemotherapy for solid tumors.

• Consistent efficacy and safety results were observed across regions, with similar median outcomes in both Eastern and Western populations.

• Expansion beyond lung cancer includes a global phase 3 trial in frontline colorectal cancer, with encouraging phase 2 data supporting this move.

• Multiple investigator-initiated and collaborative trials are ongoing, including partnerships with MD Anderson and Revolution Medicines.

Competitive landscape and strategic positioning

• First-mover advantage in major indications like lung cancer is seen as critical for physician adoption and commercial success.

• Ivonescimab is positioned as both first-in-class and best-in-class, with four successful phase 3 readouts, setting a high bar for competitors.

• Competitors face challenges in differentiation, as modifying molecules to compete with ivonescimab carries significant risk.

• Breadth and speed of development, supported by extensive data from both China and global studies, reinforce the competitive edge.

Novel combinations and future development

• Plans are underway for novel combination trials, including collaborations with Revolution Medicines to explore RAS inhibitors and with various ADC platforms.

• Strategic advantage lies in the ability to pursue multiple combination approaches, adapting to evolving standards of care in oncology.

• The company is approached by other firms seeking to combine their therapies with ivonescimab, highlighting its leadership position.